WEBULL
WebtradeDownload

ImmunityBio (IBRX) Could Be 39% Undervalued After Key Bladder Cancer Trial Milestone

Simply Wall St · 1d ago

ImmunityBio (IBRX) has reached a key clinical inflection point, completing the database lock for its pivotal QUILT-2.005 trial in BCG-naïve bladder cancer. The trial now moves to final efficacy analysis and an expected supplemental FDA filing.

ImmunityBio’s recent clinical headlines land after a powerful run, with the share price up 16.76% on a 90‑day basis but down 12.82% over the past week, and a very large year to date share price return of 327.72% alongside a 1 year total shareholder return of 266.10%. This points to strong longer term momentum despite short term volatility.

Scan beyond ImmunityBio and review other cancer and biotech plays with strong momentum using the hand picked 37 healthcare AI stocks as a starting shortlist.

After ImmunityBio’s sharp multi month surge and this week’s pullback, the practical question is simple: Does it make more sense to pay up now or wait for a cooler entry before the valuation work stacks up for you?

Most Popular Narrative: 39% Undervalued

ImmunityBio’s most followed valuation story pegs fair value at $14.25 against a last close of $8.64. This signals a wide gap that supporters link directly to ambitious growth and margin assumptions embedded in that framework.

The integration of AI driven tools like askIB into R&D, manufacturing and commercial operations, along with the NANT Leonardo robotic cell manufacturing platform, is aimed at higher throughput and lower unit costs. This can support margin improvement as volumes scale and help narrow losses over time.

See why 18 investors see ImmunityBio as 39% undervalued.

Result: Fair Value of $14.25 (UNDERVALUED)

Still, the ImmunityBio story can change quickly if Anktiva uptake is slower than analysts expect or if future trials fail to broaden approved indications.

Find out about the key risks to this ImmunityBio narrative.

Next Steps

Sentiment on ImmunityBio is split. This means the potential advantage comes from doing your own research now instead of following the crowd, starting with the 3 key rewards and 1 important warning sign.

Looking for more ImmunityBio investment ideas?

If you stop at ImmunityBio, you miss the wider opportunity set. Use the Simply Wall St Screener to quickly surface other stocks that fit your criteria.